Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP)
Brand
BD Pharmingen™
Characteristics
Fas (CD95, APO-1) is a 45 kDa cell surface protein that mediates apoptosis when cross-linked with agonistic anti-Fas antibodies or by Fas ligand (FasL, CD178). Fas belongs to the TNF (Tumor Necrosis Factor)/NGF (Nerve Growth Factor) receptor family, and is expressed in various tissues and cells including the thymus, liver, ovary and lung. CD178 (FasL), a member of the TNF cytokine family, induces apoptosis by binding to Fas, its cell-surface receptor. FasL may exist as either membrane bound or soluble forms and is expressed by activated T and NK cells. FasL may also be constitutively expressed in some immunologically privileged sites, e.g., eye and testis. Fas and FasL play an important role in the induction of apoptosis, and thus regulate a variety of immunological responses. The NOK-1 antibody clone has been reported to recognize human FasL, recognizing both the membrane bound (FasL) and soluble (sFasL) forms. It is reported that the epitope for NOK-1 has been mapped to the COOH-terminus of FasL, at the region implicated in Fas binding. FasL and sFasL have been reported to migrate at reduced molecular weights of 40 and 26 kDa, respectively. However, the molecular weights observed in a particular sample may vary according to FasL and sFasL glycosylation and breakdown patterns as described in the literature. The NOK-1 antibody clone is not recommended for the western blot application. Flow cytometric analysis of human Fas Ligand (FasL) on natural killer cells (CD16+) analyzed on a FACScan™ . Peripheral blood mononuclear cells were cultured for 3 hours in media alone (left panel) or with ionomycin plus the metalloprotease inhibitor, KB8301 (right panel). KB8301 blocks FasL cleavage resulting in high levels of cell surface FasL. The cells were stained with purified anti-human FasL (clone NOK-1, Cat. No. 556372), followed by biotinylated goat anti-mouse Igs. The cells were then incubated with normal mouse serum before adding FITC-conjugated anti-human CD16 (Cat. No. 555406) and Streptavidin-PE (Cat. No. 554061). Immunoprecipitation/western blot analysis of human FasL. Lane 1, FasL was precipitated from human peripheral blood mononuclear cells (PBMC's) with clone NOK-1 (Cat. No. 556372) and detected by western blot analysis with clone G247-4 (Cat. No. 556387). Lane 2, PBMC were immunoprecipitated with a mouse IgG1 isotype control, followed by western blot analysis with clone G247-4. The bands above and below the 40 kDa FasL band in lane 1 and lane 2 represent the heavy and light chain of IgG used for immunoprecipitation.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store undiluted at 4°C.
Orlinick, Elkon, Chao: "Separate domains of the human fas ligand dictate self-association and receptor binding." in: The Journal of biological chemistry, Vol. 272, Issue 51, pp. 32221-9, (1998) (PubMed).
Oyaizu, Adachi, Hashimoto, McCloskey, Hosaka, Kayagaki, Yagita, Pahwa: "Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 158, Issue 5, pp. 2456-63, (1997) (PubMed).
Sieg, Smith, Yildirim, Kaplan: "Fas ligand deficiency in HIV disease." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 11, pp. 5860-5, (1997) (PubMed).
Villunger, Egle, Marschitz, Kos, Böck, Ludwig, Geley, Kofler, Greil: "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance." in: Blood, Vol. 90, Issue 1, pp. 12-20, (1997) (PubMed).
Walker, Saas, Dietrich: "Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 158, Issue 10, pp. 4521-4, (1997) (PubMed).
Kayagaki, Kawasaki, Ebata, Ohmoto, Ikeda, Inoue, Yoshino, Okumura, Yagita: "Metalloproteinase-mediated release of human Fas ligand." in: The Journal of experimental medicine, Vol. 182, Issue 6, pp. 1777-83, (1996) (PubMed).
Zavazava, Krönke: "Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes." in: Nature medicine, Vol. 2, Issue 9, pp. 1005-10, (1996) (PubMed).
Tanaka, Suda, Takahashi, Nagata: "Expression of the functional soluble form of human fas ligand in activated lymphocytes." in: The EMBO journal, Vol. 14, Issue 6, pp. 1129-35, (1995) (PubMed).
Takahashi, Tanaka, Brannan, Jenkins, Copeland, Suda, Nagata: "Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand." in: Cell, Vol. 76, Issue 6, pp. 969-76, (1994) (PubMed).
Target
FASL
(Fas Ligand (TNF Superfamily, Member 6) (FASL))